May 26, 2020

Background: The saga of Remdesivir for treatment of COVID-19 continues. We previously covered two studies of this drug on REBEL EM (Link is HERE & Link is HERE). One trial (≈200pts) showed no difference in the primary outcome of median time to clinical improvement and the second trial was a compassionate release study which gave us no real clinical information due to its design. A third study was mentioned in the first post from the NIAID, but we didn’t really review it, as much as mention it, as no data was made available.  It was a little teaser from the National Institute of Allergy and Infectious Diseases (NIAID). Despite these facts the FDA approved remdesivir for use and we have had no robust data supporting its use except for the tease of the NIAID study.  Part 1 of the NIAID trial was just published in the NEJM as a preliminary report and we will review here on this post: Remdesivir ACTT-1.